National Institute of Allergy & Infectious Diseases (NIAID)
31 Center Drive MSC 2520
Building 31, Room 7A-50
256 articles with National Institute of Allergy & Infectious Diseases (NIAID)
Jaguar Health Subsidiary Receiving Preclinical Services from the NIAID for New Preclinical Study Initiated January 6, 2021 for Lechlemer Plant-Based Drug Candidate for the Symptomatic Relief of Diarrhea from Cholera
Jaguar Health, Inc. announced that the 28-day preclinical toxicology and safety study in dogs began today, January 6, 2021, to support development of lechlemer, the second generation, plant-based anti-secretory drug candidate of Napo Pharmaceuticals, Jaguar's wholly owned subsidiary, for the symptomatic relief of diarrhea from cholera.
Dr. Anthony Fauci, Director of the National Institute of Allergy and Infectious Diseases at the National Institutes of Health will join the University of Chicago Harris School of Public Policy on March 4 for a conversation hosted by its dean, Katherine Baicker, who will award Dr. Fauci the 2020 Harris Dean's Award.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for December 8, 2020.
Researchers with the U.S. National Institutes of Allergy and Infectious Diseases (NIAID) published a letter in The New England Journal of Medicine describing the three-month immunogenicity levels in Moderna’s mRNA-1273 vaccine.
Moderna’s COVID-19 Vaccine Candidate Meets its Primary Efficacy Endpoint in the First Interim Analysis of the Phase 3 COVE Study
Moderna intends to submit for an Emergency Use Authorization (EUA) with U.S. FDA in the coming weeks and expects the EUA to be based on the final analysis of 151 cases and a median follow-up of more than 2 months
Eli Lilly is continuing their other trial in mild-to-moderate COVID-19 patients and stated they “remain confident … that bamlanivimab monotherapy may prevent progression of disease for those earlier in the course of COVID-19.”
National Institutes of Health Launches its ACTIV-5 “Big Effect Trial” Evaluating Humanigen’s Lenzilumab™ as Potential COVID-19 Therapy
Lenzilumab among the promising agents selected for ACTIV program from pool of approximately 400 candidate agents
The trial, part of a collaboration with U.S. government agencies including BARDA, the FDA and the NIH, will evaluate the safety, efficacy and tolerability of the anti-SARS-CoV-2 hyperimmune globulin that, if proven safe and effective, could be a potential treatment for COVID-19
Indee Labs announces a grant award from the National Institute of Allergy and Infectious Diseases to develop the µVS Delivery SystemTM for modified regulatory T cells
SRI International Awarded Contract Worth Up to $100M from National Institute of Allergy and Infectious Diseases for Radiation/Nuclear Medical Countermeasures
Grant extends SRI's long history of collaborations with the National Institutes of Health
Lilly Initiates Phase 3 Trial of LY-CoV555 for Prevention of COVID-19 at Long-Term Care Facilities in Partnership with the National Institute of Allergy and Infectious Diseases (NIAID)
More than 40 percent of coronavirus deaths in the U.S. linked to long-term care facilities; urgent need for therapeutic strategies to prevent COVID-19 in this vulnerable population
Moderna published data in The New England Journal of Medicine late yesterday in non-human primate studies of its MRNA-1273 vaccine against COVID-19.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 10, 2020.
IAVI and Scripps Research Join Efforts with the U.S. National Institutes of Health to Expedite Development of Globally Accessible and Affordable HIV Antibody Combination Products
Today during the global conference AIDS 2020: Virtual , IAVI, a scientific research organization dedicated to addressing urgent unmet health needs including HIV and tuberculosis, announced an innovative collaboration with Scripps Research and the National Institute of Allergy and Infectious Diseases (N
The National Institute of Allergy & Infectious Diseases (NIAID) has founded a new clinical trials network focused on enrolling volunteers in clinical trials for COVID-19 vaccines and monoclonal antibodies.
ChromaDex and the NIH-NIAID Rocky Mountain Laboratories Announce Study to Assess the Therapeutic Potential of Niagen® in COVID-19 Animal Models
Study on ChromaDex’s NR ingredient to be conducted at NIH-NIAID’s Rocky Mountain Labs, one of the few Biosafety Level 4 labs in the U.S.
Regeneron Announces Start of REGN-COV2 Phase 3 COVID-19 Prevention Trial in Collaboration with National Institute of Allergy and Infectious Diseases (NIAID)
Anti-viral antibody cocktail REGN-COV2 is also in Phase 2/3 treatment trials following positive Phase 1 safety review
NIH Report on Phase 2 Clinical Trial of BiondVax's M-001 Universal Influenza Vaccine Candidate Concludes Both Primary Endpoints Achieved
BiondVax Pharmaceuticals Ltd. announced the completion of the clinical study report of a Phase 2 clinical trial of the Company's M-001 universal influenza vaccine candidate.
Fauci, a longtime infectious disease expert, said COVID-19 is the stuff of nightmares in the way it has quickly spread across the globe, infected millions of people and contributed to the deaths of more than 408,000 people.
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 10, 2020.